Active Not Recruiting OBSERVATIONAL NCT07018427
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Unresectable Locally Advanced, Recurrent, or Metastatic HER2-Negative Breast Cancer: A Multicenter Real-World Study
Sponsor: Peking University Cancer Hospital & Institute
Conditions
Breast Cancer Breast Neoplasms HR+, HER2-, Advanced Breast Cancer Triple Negative Breast Cancer
Interventions
Sacituzumab Govitecan Monotherapy or Combination Therapy
Updated 1 time since 2025 Last updated: Jun 4, 2025 Started: May 1, 2023 Primary completion: May 1, 2025 Completion: Sep 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07018427, this observational or N/A phase trial focuses on Breast Cancer and Breast Neoplasms and remains ongoing. Sponsored by Peking University Cancer Hospital & Institute, it has been updated 1 time since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Active Not Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking University Cancer Hospital & Institute
Data source: Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .